Accelerating Sales of Eisai and Biogen’s Alzheimer’s Drug Leqembi in Japan

Sales Acceleration in Japan::
Despite a slow start in the US, sales of Eisai and Biogen's Alzheimer's drug Leqembi are beginning to accelerate in Japan.

Global Sales Increase::
The drug has seen a significant surge in global sales, with the patient count more than doubling and sales reaching nearly $19 million in the first quarter of 2024, a nearly threefold increase from the previous quarter.

Revenue Projections::
Eisai has set a revenue target of 56.5 billion yen (approximately $361 million) for Leqembi in the 2024 fiscal year, which is seen as more realistic and achievable by analysts.

Patient Growth::
The number of patients taking Leqembi has increased substantially, with the drug now being used by almost 2.5 times the number of patients as at the end of 2023.

Future Developments::
Biogen and Eisai are working on a more convenient injectable form of Leqembi, which they believe will further boost sales and patient uptake.